GlucoTrack

GlucoTrack Debt/EBITDA

Total Debt to EBITDA Ratio of GlucoTrack (GCTK) as of Oct 30, 2026.

Debt/EBITDA

-0.00

YoY

-88.83%

Last updated:

Total Debt to EBITDA Ratio of GlucoTrack is 2025 -0.00 . Total Debt to EBITDA Ratio of GlucoTrack was 2024 -0.02 . It decreases by -88.83% higher compared to the previous year.

The GlucoTrack Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
0.03 USD
Jan 1, 2019
0.11 USD
Jan 1, 2020
-0.12 USD
Jan 1, 2021
-0.06 USD
Jan 1, 2022
-0.04 USD
Jan 1, 2023
-0.03 USD
Jan 1, 2024
-0.02 USD
Jan 1, 2025
-0.00 USD
The GlucoTrack Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.00-88.83%
-0.02-33.60%
-0.03-37.50%
-0.04-29.27%
-0.06-46.86%
-0.12-210.71%
0.11+316.82%
0.03+47.55%
0.02-39.68%
0.03-16.81%
0.03-79.81%
0.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlucoTrack Stock analysis

What does GlucoTrack do? GlucoTrack, Inc. makes money by selling non-invasive glucose monitoring devices and related software solutions to people with diabetes and pre-diabetes. The company's GlucoTrack device provides glucose level readings without finger sticks, targeting Type II diabetes and prediabetes users. It also develops an implantable continuous glucose monitor for Type I diabetes and insulin-dependent Type II diabetes patients. The firm offers companion applications and cloud-based solutions to deliver real-time, data-driven tools for diabetes management. Its primary customers are individuals managing diabetes through non-invasive monitoring solutions, with a focus on Type II diabetes and pre-diabetes segments. GlucoTrack, Inc. generates revenue through the commercialization of its non-invasive glucose monitor and the development of its implantable continuous glucose monitor. The company's products are designed for specific diabetes segments: Type II diabetes and prediabetes users for the GlucoTrack device, and Type I diabetes and insulin-dependent Type II diabetes patients for the implantable monitor. The firm's cloud-based platform and companion apps are integral to its service offering, providing personalized diabetes management tools. Revenue streams include device sales and software services for these targeted user groups. The company's business model centers on direct sales of its GlucoTrack device and implantable monitor to diabetes patients. It focuses on Type II diabetes and prediabetes for the non-invasive monitor, while the implantable version targets Type I diabetes and insulin-dependent Type II diabetes. The firm's cloud-based solutions and companion applications are sold as part of the overall diabetes management platform. Revenue is derived from both hardware sales and subscription-based software services for these specific patient segments. GlucoTrack is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlucoTrack stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio GlucoTrack since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's GlucoTrack with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GlucoTrack

All Key Metrics — GlucoTrack